Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode by Gillissen, B. et al.
Targeted therapy of the XIAP/proteasome pathway
overcomes TRAIL-resistance in carcinoma
by switching apoptosis signaling to a
Bax/Bak-independent ‘type I’ mode
B Gillissen1, A Richter1, A Richter1, T Overkamp1, F Essmann2, PG Hemmati1, R Preissner1, C Belka3 and PT Daniel*,1,4
TRAIL is a promising anticancer agent, capable of inducing apoptosis in a wide range of treatment-resistant tumor cells. In ‘type
II’ cells, the death signal triggered by TRAIL requires amplification via the mitochondrial apoptosis pathway. Consequently,
deregulation of the intrinsic apoptosis-signaling pathway, for example, by loss of Bax and Bak, confers TRAIL-resistance and
limits its application. Here, we show that despite resistance of Bax/Bak double-deficient cells, TRAIL-treatment resulted in
caspase-8 activation and complete processing of the caspase-3 proenzymes. However, active caspase-3 was degraded by the
proteasome and not detectable unless the XIAP/proteasome pathway was inhibited. Direct or indirect inhibition of XIAP by RNAi,
Mithramycin A or by the SMAC mimetic LBW-242 as well as inhibition of the proteasome by Bortezomib overcomes TRAIL-
resistance of Bax/Bak double-deficient tumor cells. Moreover, activation and stabilization of caspase-3 becomes independent of
mitochondrial death signaling, demonstrating that inhibition of the XIAP/proteasome pathway overcomes resistance by
converting ‘type II’ to ‘type I’ cells. Our results further demonstrate that the E3 ubiquitin ligase XIAP is a gatekeeper critical for the
‘type II’ phenotype. Pharmacological manipulation of XIAP therefore is a promising strategy to sensitize cells for TRAIL and to
overcome TRAIL-resistance in case of central defects in the intrinsic apoptosis-signaling pathway.
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TRAIL (tumor necrosis factor-related apoptosis-inducing
ligand/Apo2L) is capable of inducing cell death in a wide
range of cancers resistant to conventional therapy without
apparent toxic side effects to normal tissues.1 The expression
of TRAIL-R1 is an independent prognostic parameter, for
example, in colon carcinoma and high expression of TRAIL-
R1 correlates with prolonged disease-free survival.2 Further-
more, TRAIL and the death ligands CD95L/FasL and TNFa
sensitize tumor cells for ionizing radiation- and drug-induced
apoptosis3,4 albeit toxicity profiles may hamper (TNFa) or
even preclude (CD95L/FasL) clinical use.
Death ligands initiate receptor oligomerization and forma-
tion of the death inducing signaling complex (DISC), resulting
in activation of the initiator caspase-8. In type I cells, active
caspase-8 directly mediates sufficient activation of the
effector caspase-3 that triggers execution of apoptosis. In
contrast, in type II cells, the death signal requires amplification
via activation of the intrinsic cell death pathway5 through
caspase-8-mediated cleavage and activation of Bid, a
BH3-only protein of the Bcl-2 family.6
Thus, proteins of the Bcl-2 family are key regulators of both
mitochondrial and death receptor-mediated apoptosis. Mem-
bers of the family show homology in at least one of the four
Bcl-2 homology (BH) domains. Anti-apoptotic proteins of this
family (Bcl-2, Bcl-xL Bcl-w, Mcl-1 and Bfl-1/A1) are character-
ized by the presence of all four BH domains. Pro-apoptotic
members can be subdivided into the multidomain BH123
homologs (Bax and Bak), and the proteins of the BH3-only
subfamily (Bad, Bim, Puma, Noxa, Nbk/Bik, Bmf, Bnip3, Hrk
and Bid).7
Activated, truncated (t)Bid triggers Bax activation to induce
mitochondrial membrane permeabilization (MMP) accom-
panied by the release of apoptogenic factors from the
mitochondrial inter-membrane space into the cytosol. One of
these factors, cytochrome c, associates with APAF-1 and pro-
caspase-9 to form the ‘apoptosome’, a platform that facilitates
autocatalytic activation of caspase-9, which in turn triggers the
effector caspases. Another pro-apoptotic factor released
uponMMP is SMAC/DIABLO.8,9 SMAC potentiates apoptosis
by neutralizing cytosolic inhibitor of apoptosis proteins (IAPs).
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IAPs, a family of eight human analogs including cIAP1, cIAP2
andXIAP, the latter themost potent one,10 prevent inadvertent
caspase activation XIAP does this by binding directly to
caspases through its baculovirus IAP repeat (BIR) domain.
Many human tumors express high levels of IAPs including
XIAP and aberrant expression of IAPs has been linked to
therapy resistance and poor prognosis.11 In addition to the
upregulation of XIAP, deregulation of pro- and anti-apoptotic
Bcl-2 family proteins is a central mechanism involved in
TRAIL-resistance.12,13 We have recently shown that loss of
Bax, despite expression of its homologBak, confers resistance
to TRAIL-induced apoptosis. However, inhibition of the
endogenous Bak antagonist Mcl-1 enables TRAIL to kill cells
via Bak.14
Here, we show that inhibition of the XIAP/proteasome
pathway renders Bax/Bak double-deficient carcinoma cells
sensitive to TRAIL. Because mitochondrial amplification of the
death receptor signal is impossible in these cells, down-
regulation of XIAP converts type II into type I cells. These
results show that in TRAIL-induced apoptosis, XIAP dictates
the type II mode of cell death and that switching the cell death
mode is a promising strategy to overcome TRAIL-resistance in
cells with central defects in mitochondrial apoptosis signaling.
Results
To evaluate strategies to overcome resistance to TRAIL, we
addressed the role of XIAP in a HCT116 colon cancer cell line
model. We compared the impact of Mcl-1 and XIAP down-
regulation on TRAIL-treated isogenic HCT116 wt cells,
HCT116 Bax-deficient cells (termed HCT116 Bax ) and
cells devoid of Bax and Bak (termed HCT Bax /Bak ).15
Specific loss of protein expression was achieved by knockout
of bax16 and stable shRNA-mediated Bak knockdown17 and
was verified by western blot analysis (Figures 1a and c can be
compared because they represent the same membranes).
HCT116 cells were transfected with control-, Mcl-1- or
XIAP-siRNA and downregulation of the respective proteins
was confirmed by western blot analysis (figure1, left). Upon
downregulation of Mcl-1 or XIAP, cells were incubated with
50 ng/ml TRAIL for 24 h and induction of apoptosis was
analyzed by flow cytometric measurement of cells with a
hypodiploid DNA content. TRAIL-treatment resulted in apop-
totic DNA fragmentation in about 28% of the HCT116 wt cells.
Sensitivity toward TRAIL was increased by knockdown of
Mcl-1 and even more by XIAP knockdown, about 35 and 42%
of the respective cells were apoptotic (Figure 1a, right).
Unlike HCT116 wt cells, Bax-deficient HCT116 cells were
resistant to TRAIL-induced apoptosis. However, Mcl-1 or
XIAP downregulation rendered these cells susceptible to
TRAIL. Compared with 6% of control cells, TRAIL-induced
apoptosis increased up to 32 and 41% upon Mcl-1 or XIAP
downregulation, respectively (Figure 1b, right).
In contrast, TRAIL-resistance of HCT116 Bax /Bak cells
could not be overcome by inhibition of Mcl-1. However,
downregulation of XIAP strongly sensitized these double-
deficient cells for TRAIL-induced apoptosis. Cells transfected
with control- or Mcl-1-siRNA and treated with TRAIL showed
apoptotic DNA fragmentation in o6% of the cells, which
increased to 34% upon XIAP downregulation (Figure 1c, right).
Annexin V-FITC/propidium iodide (PI) staining of HCT116
wt and HCT116 Bax /Bak cells upon TRAIL-treatment
confirmed that cell death occurs by apoptosis and that TRAIL-
resistance of HCT116 Bax /Bak cells can be overcome by
downregulation of XIAP (Supplementary Figure S1). Further-
more, XIAP downregulation overrides resistance of Bcl-2 or
Bcl-xL overexpressing HCT116 cells, supporting our finding
that upon TRAIL-treatment XIAP-deficient cells die indepen-
dently of a Bcl-2 family protein regulated pathway
(Supplementary Figure S2).
As caspase-8 and -3 are crucial for TRAIL-induced
apoptosis, we next examined to which extent Bax/Bak
deficiency impacts on processing of caspase-8 and -3. We
treated HCT116 wt and Bax /Bak cells with TRAIL and
analyzed the cleavage pattern of these caspases. Pro-
caspase-8 and -3 levels are comparable in both cell lines,
respectively (Figure 2a, left). Following TRAIL-treatment, pro-
caspase-8 is cleaved in both cell lines and processed to its
active subunits to a similar extent. Interestingly, in both cell
lines, caspase-8 activation goes along with cleavage of the
pro-caspase-3 zymogen, indicating that caspase-8 activation
upon TRAIL-treatment is sufficient to cleave pro-caspase-3.
Nevertheless, cleavage of pro-caspase-3 is accompanied by
processing to its active p18/p16 subunits only in TRAIL-
sensitive HCT116 wt cells. In contrast, TRAIL-resistant
HCT116 Bax /Bak cells showed no processing of
caspase-3 to its active subunits (Figure 2a, left). Thus, in
contrast to cleavage of the pro-caspase-3 zymogen, which is
independent of Bax and Bak, processing of pro-caspase-3 to
its active subunits relies on an intact intrinsic mitochondrial
pathway.
To analyze if the ubiquitin ligase activity of XIAP mediates
degradation of the caspase-3 subunits we knocked down
XIAP. In HCT116 Bax /Bak cells transfected with control
siRNA, TRAIL-treatment resulted in pro-caspase-3 cleavage
without generation of the active caspase-3. In contrast,
downregulation of XIAP in combination with TRAIL caused
full processing of pro-caspase-3 to its active subunits
(Figure 2a, right). This indicates that caspase-8 activity
triggered by TRAIL is sufficient to cleave pro-caspase-3 while
caspase-3 activation is prevented by XIAP-mediated degra-
dation of processed caspase-3.
To investigate proteasomal degradation of active caspase-3,
we treated HCT116 wt and Bax /Bak cells with non-toxic
concentrations of the proteasome inhibitor MG132. In
HCT116 wt cells, TRAIL-induced caspase-3 activation is
increased upon additional treatment with MG132 (Figure 2b,
left). More importantly, in HCT116 Bax /Bak cells, TRAIL
alone induced the cleavage of pro-caspase-3 without detect-
able levels of active subunits, whereas the combination
induced full caspase-3 processing to its active subunits
(Figure 2b, right).
In agreement with increased caspase-3 activation, TRAIL-
induced apoptosis was increased in HCT116 wt cells upon
additional inhibition of the proteasome. Moreover, MG132
treatment overcame TRAIL-resistance of Bax/Bax deficient
HCT116 cells (Figure 2c). Like MG132, bortezomib (BZM),
the first therapeutic proteasome inhibitor, sensitized HCT116
wt cells for TRAIL-induced apoptosis and overcame TRAIL-
resistance of HCT116 Bax /Bak cells (Figure 2d),
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indicating that sensitization towards TRAIL-induced apoptosis
by inhibition of the proteasome is caused by stabilization of
active caspase-3 and does not rely on the intrinsic apoptotic
pathway.
To further investigate the mode of caspase-3 activation in
the presence or absence of XIAP in relation to type I/II
apoptosis signaling, we analyzed TRAIL-induced apoptosis in
cells subjected to caspase-8 and Bid downregulation. In
HCT116wt cells, TRAIL-induced apoptosis was accompanied
by pro-caspase-8 processing, Bid cleavage and processing of
pro-caspase-3 to active subunits (Figure 3a). Downregulation
of caspase-8 or Bid inhibited induction of apoptosis. But in
contrast to caspase-8 downregulation, which blocked TRAIL-
induced pro-caspase-3 cleavage, Bid knockdown did not
impair pro-caspase-3 cleavage, indicating that most of the
detected pro-caspase-3 processing occurs upstream of the
mitochondrial amplification loop. However, although pro-
caspase-3 was cleaved, subunits were decreased after Bid
downregulation (Figure 3a, right), indicating that processing of
pro-caspase-3 to the active subunits depends on Bid.
Additional knockdown of XIAP restored the induction of
apoptosis by TRAIL in HCT116 wt cells with Bid knockdown
(Figure 3b, left) and resulted in complete cleavage of pro-
caspase-8 and pro-caspase-3, accompanied by high levels of
the p18 caspase-3 subunit (Figure 3b, right). Knockdown of
caspase-8 impaired induction of apoptosis, Bid cleavage and
caspase-3 cleavage in the absence or presence of XIAP
knockdown (Figures 3a and b). These results were confirmed
in HCT116 Bax /Bak cells in which XIAP downregulation
overcomes TRAIL-resistance (Figure 3c, left) and induction of
apoptosis is accompanied by pro-caspase-8 and Bid clea-
vage. Furthermore, absence of XIAP facilitated processing of
pro-caspase-3 to the active subunits (Figure 3c, right). These
events were inhibited by caspase-8 knockdown but not by
knockdown of Bid. Thus, inhibition of XIAP enables TRAIL to
activate caspase-3 and to induce apoptosis despite combined
loss of Bid, Bax and Bak, clearly demonstrating that cell death
induction is independent of the intrinsic apoptotic pathway and
follows a type I mode.
Next, we compared the time-dependent regulation of
TRAIL-induced apoptosis in HCT116 wt and in HCT116
Bax /Bak cells after XIAP downregulation. Western blot
analysis of TRAIL-treated HCT116 wt cells revealed early
caspase-8 processing, accompanied by Bid activation,
indicated by increased tBid levels detectable already after
4 h of treatment (Figure 4a, left). Furthermore, TRAIL-induced
caspase-8 and Bid activation were accompanied by cyto-
chrome c and SMAC release coinciding with caspase-3
activation and PARP cleavage (Figure 4a, left). Western blot
analysis further revealed a time-dependent degradation of
XIAP in response to TRAIL, which may reflect autoubiquitina-
tion and subsequent proteasomal degradation or caspase-
mediated cleavage.18
To analyze dissipation ofmitochondrial membrane potential
(DCm) upon TRAIL-treatment, cells were incubated with the
fluorochrome JC-1, which exhibits membrane potential-
dependent accumulation in mitochondria. Measurement of
JC-1-fluorescence intensity by flow cytometry showed a time-
dependent accumulation of HCT116 wt cells with disruption of
DCm upon TRAIL-treatment. This was an early event
detectable already after 6 h of treatment that precedes DNA
fragmentation (Figure 4b, left).
In analogy, HCT116 Bax /Bak cells with downregulated
XIAP showed caspase-8 and Bid processing as early events
during TRAIL-induced apoptosis, detectable 4 h after treat-
ment. In contrast to HCT116 wt cells, Bid cleavage did,
however, not coincide with cytochrome c or SMAC release.
Both occurred only late upon TRAIL-treatment, detectable
Figure 1 Silencing of XIAP by RNA interference enables TRAIL to induce Bax/
Bak-independent cell death in type II cells. HCT116 wt, Bax and Bax /Bak
cells were transfected with control-, Mcl-1- or XIAP-siRNA. After 24 h, protein
extracts were prepared and analyzed by western blot. Mcl-1 and XIAP
downregulation and expression status for Bax and Bak for respective HCT116
cell lines is shown on the left of (a–c). Cells were then treated with 50 ng/ml TRAIL,
cultured for additional 24 h and apoptotic cells were determined by flow cytometric
measurement of the cellular DNA content. (a) HCT116 wt cells were sensitized for
TRAIL-induced apoptosis upon Mcl-1 or XIAP downregulation. (b) Mcl-1 as well as
XIAP downregulation overcomes TRAIL-resistance of HCT116 Bax cells. (c)
Downregulation of Mcl-1 fails to overcome TRAIL-resistance of HCT116 Bax /
Bak cells. In contrast, knockdown of XIAP enables TRAIL to kill Bax/Bak-
deficient HCT116 cells. Results are given as mean values±S.D. from three
experiments for the respective cell lines in the right part of (a–c)
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after 12 h (Figure 4a, right). This indicates that tBid failed to
trigger the mitochondrial pathway. Nevertheless, TRAIL-
treatment in the absence of XIAP resulted in early caspase-
3 activation, which coincided with PARP cleavage (Figure 4a,
right). Furthermore, despite early induction of apoptosis but in
line with the delayed kinetic of cytochrome c and SMAC
release, MMP was also a late event in these cells. Interest-
ingly, and in contrast to HCT116 wt cells, breakdown of DCm
followed DNA fragmentation upon TRAIL-treatment in
HCT116 Bax /Bak cells (Figure 4b, right), indicating that
MMP occurs late and coincides with cellular demise instead of
playing an early, regulatory role. In summary, XIAP down-
regulation facilitates TRAIL-induced apoptosis signaling that
is independent of MMP, cytochrome c and SMAC release,
which all seem to be secondary effects.
Time response analysis of Annexin V-FITC/PI staining
upon TRAIL-treatment confirms the different cell death mode.
Early apoptotic cells were detectable already 4 h after TRAIL-
treatment in HCT116 wt cells and in HCT116 Bax /Bak
cells with downregulated XIAP. However, HCT116 wt cells
tend toward early occurrence of a late apoptotic phenotype,
detectable after 8 h of TRAIL-treatment. In contrast, late
apoptotic HCT116 Bax /Bak cells were detectable after
12 h at the earliest (Supplementary Figure S3). Interestingly at
this time point, HCT116 Bax /Bak cells also display MMP
and cytochrome c release (Figures 4a and b). Taken together,
the results indicate that MMP and cytochrome c release,
which occur early in type II and late in type I cells, are
accompanied by a late apoptotic/necrotic phenotype of the
cells.
Given the therapeutic impact of our findings, we next asked
if small molecules, known to downregulate or inhibit XIAP, can
overcome the resistance of Bax/Bak-deficient cells. The
antitumor agent Mithramycin A (Mit A) sensitizes various
cancer cell lines to TRAIL-mediated apoptosis by down-
regulation of XIAP.19 To confirm downregulation of XIAP by
Mit A, we treated HCT116 wt and HCT116 Bax /Bak cells
with different concentrations of Mit A for 24 h. Subsequent
analysis of XIAP levels confirmed reduced XIAP expression
(Figure 5a). This is accompanied by an increased TRAIL
sensitivity in HCT116 wt cells, mainly due to Bax/Bak-
dependent, additive toxicity of Mit A. Furthermore, Mit A
treatment efficiently overcame TRAIL-resistance of Bax/Bak-
deficient HCT116 cells (Figure 5a, lower panel).
Additionally, we targeted XIAP directly by use of the SMAC
mimetic LBW-242, a synthetic small molecule that binds to
and inhibits IAPs. Treatment of HCT116 cells with LBW-242 in
addition to TRAIL reduced XIAP expression (Figure 5b, upper
panel, lanes 2 and 4), which might be due to cleavage of
XIAP by caspase-3 in a feedback loop or autoubiquitylation
and proteasomal degradation. Furthermore, inhibition of XIAP
resulted in an increase of TRAIL-induced apoptosis
Figure 2 TRAIL-induces pro-caspase-3 processing in Bax/Bak double-deficient
cells but fails to overcome inhibition by XIAP and proteasomal caspase-3
degradation. (a) HCT116 wt and Bax /Bak cells were treated with 50 ng/ml
TRAIL and pro-caspase-8 and -3 processing were analyzed by immunoblotting.
TRAIL-treatment induced cleavage of pro-caspase-8 and -3 in both cell lines.
Cleavage of pro-caspase-8 is accompanied by generation of its active subunits. In
contrast, processing of pro-caspase-3 to its active subunits is detectable only in
HCT116 wt but not in HCT116 Bax /Bak cells (left). Additional downregulation
of XIAP in combination with TRAIL caused full processing of pro-caspase-3 to its
active subunits in HCT116 Bax /Bak cells (right). (b) HCT116 wt and Bax /
Bak cells were incubated with the proteasome inhibitor MG132 prior to TRAIL-
treatment. Upon inhibition of the proteasome, TRAIL-treatment resulted in full
processing of pro-caspase-3 to its active subunits in both cell lines. (c, d) In addition
to TRAIL, HCT116 wt and Bax /Bak cells were treated with 1 mM of MG132 (c)
or with 1 mM of bortezomib (BZM) (d). Cells were cultured for 24 h, harvested and
apoptotic cells were determined by flow cytometric measurement of cellular DNA
content. HCT116 wt cells were sensitized for TRAIL-induced apoptosis by MG132
or BZM. Furthermore, inhibition of the proteasome enables TRAIL to kill
Bax/Bak-deficient HCT116 cells
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in HCT116 wt cells and, more importantly, overcame
TRAIL-resistance of Bax/Bak double-deficient cells (Figure 5b,
lower panel). The re-sensitization of HCT116Bax /Bak cells
is caused by the complete processing of pro-caspase-3 since
active subunits were detectable only after the combined
treatment with TRAIL and LBW-242 (Figure 5b, upper panel).
Thus, like BZM, MG132 or Mit A, LBW-242 overcomes TRAIL-
resistance and facilitates TRAIL-induced caspase-3 activation
and induction of apoptosis in a type I manner.
To analyze if XIAP plays a similar role in cell death induced
by other death receptors, we treated cells with TNFa or
CD95L/FasL. In HCT116 wt cells, TNFa treatment resulted in
weak induction of apoptosis; B10% of the cells were
apoptotic (Figure 6a). Compared with TNFa, CD95L/FasL-
induced DNA fragmentation was more pronounced and 24%
of the cells underwent apoptosis. However, upon XIAP
downregulation TNFa as well as CD95L/FasL-induced apop-
tosis was increased up to 16% and 37%, respectively. In
contrast to HCT116 wt cells, neither TNFa nor CD95L/FasL
induced apoptosis in HCT116 Bax /Bak cells. However,
resistance was overcome by XIAP downregulation, resulting
in around 17% and 25% apoptotic cells upon TNFa or CD95L/
FasL treatment, respectively (Figure 6b). Altogether, these
data show that downregulation of XIAP enables death
Figure 3 Upon XIAP silencing, TRAIL-induced apoptosis and caspase-3 activation become independent of Bid, Bax and Bak. (a) HCT116 wt cells were transfected with
control-, caspase-8- or Bid-siRNA and subsequently incubated with TRAIL. TRAIL-induced DNA fragmentation was blocked by downregulation of either caspase-8 or Bid (left).
Western blot analysis confirmed downregulation of the respective proteins (right). Furthermore, western blot analysis showed that knockdown of caspase-8 blocked
pro-caspase-3 cleavage. In contrast, knockdown of Bid did not inhibit pro-caspase-3 cleavage but processing of caspase-3 to its active subunits. (b) HCT116 wt were treated
as in (a). In addition, XIAP was knocked down. Upon XIAP knockdown, TRAIL-induced apoptosis was inhibited by caspase-8 downregulation but not anymore by Bid
downregulation (left). In this setting, TRAIL-induced activation of pro-caspase-3, indicated by the active subunit, depends on caspase-8 but was independent of Bid.
(c) HCT116 Bax /Bak cells were treated as in (b). Upon XIAP downregulation, TRAIL-induced apoptosis (left) is accompanied by caspase-3 activation (right). Both can be
blocked by knockdown of caspase-8. In contrast, caspase-3 activation and apoptosis was not blocked by downregulation of Bid. Thus, inhibition of XIAP enables TRAIL to
activate caspase-3 and to induce apoptosis despite combined loss of Bid, Bax and Bak
XIAP in TRAIL-resistance of Bax/Bak deficient cells
B Gillissen et al
5
Cell Death and Disease
receptors to kill type II cells independently of themitochondrial
death machinery by switching the apoptotic-signaling path-
way from type II to type I.
Discussion
Strategies to overcome TRAIL-resistance comprise inhibition
of pro-survival signaling, for example, the NF-kB pathway,20
inhibition of the proteasome21 or inhibition of histone
deacetylases.22 The kinase inhibitors Roscovitine or Sorafe-
nib sensitize cancer cells to TRAIL through pleiotropic
mechanisms comprising facilitated DISC formation and
caspase-8 activation, downregulation of cFLIP and XIAP
and suppression of Mcl-1.14,23,24 Strategies directly targeting
the Bcl-2 family include BH3 mimetics like ABT-737 that bind
to the hydrophobic groove exposed at the surface of
antiapoptotic proteins, block their pro-survival function and
potentiate TRAIL-mediated apoptosis.25 However, cell death
still relies on the presence of Bax and Bak as MMPmediators.
Inhibition of IAPs is another promising approach to sensitize
treatment-resistant tumor cells for TRAIL. Especially the
inhibition of XIAP by small molecular SMAC mimetics
has been shown to synergize with TRAIL and to potentiate
TRAIL-induced apoptosis in various cancer cells.26,27
We addressed not only the role but also the pharmacolo-
gical targeting of XIAP in type I/II signaling. In contrast to type I
Figure 4 Mitochondrial permeability transition precedes cell death induction in HCT 116 cells but is not involved in TRAIL-induced apoptosis after downregulation of XIAP
in Bax/Bak-deficient HCT 116 cells. (a) 24 h after transfection of HCT116 wt with control siRNA (left) and HCT116 Bax /Bak with XIAP-siRNA (right), cells were treated
with TRAIL and cultured for the indicated time. Western blot analysis revealed early processing of caspase-8 and -3 and cleavage of Bid and PARP in both cell lines.
In HCT116 wt cells, cytochrome c and SMAC release into the cytosol was seen 4 h after TRAIL-treatment. In contrast, cytochrome c and SMAC release was a late event in
HCT116 Bax /Bak cells. (b) Cells were treated as described in (a), harvested and percentages of cells with loss of DCm were determined by flow cytometric
measurement of JC-1 fluorescence. In addition, percentages of apoptotic cells were determined by flow cytometric measurement of hypodiploid cells. These analyses revealed
that in HCT116 wt cells, loss of mitochondrial membrane potential precedes apoptotic DNA fragmentation. This is in contrast to HCT116 Bax /Bak cells with XIAP
downregulation, where loss of mitochondrial membrane potential, release of cytochrome c and SMAC are late events. Data expressed as mean values±S.D. from three
experiments
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cells, type II cells require activation of a mitochondrial
amplification loop to achieve full caspase activation that
depends on activation of Bid. Interestingly, a recent report
showed that loss of XIAP alleviates the need for Bid in CD95/
Fas-induced hepatocyte apoptosis in mice.28
Here, we show that TRAIL-resistance of type II carcinoma
cells with central mitochondrial death signaling defects was
overcome by inhibition of XIAP. This enabled TRAIL to induce
apoptosis in cells overexpressing the anti-apoptotic proteins
Bcl-2 or Bcl-xL or in cells deficient for the pro-apoptotic
proteins Bax, Bak, and Bid. Under these conditions, apoptosis
is not accompanied by MMP and cytochrome c or SMAC
release, indicating that cell death induction is independent of
the intrinsic pathway. This is in contrast to Bax/Bak positive
cells, where MMP and cytochrome c release precedes
apoptosis. Thus, downregulation of XIAP bypasses a cell
death blockade at the level of the mitochondria by switching
apoptosis signaling from type II to type I. This observation
Figure 5 Downregulation or inhibition of XIAP by Mithramycin A or LBW-242, respectively, overcomes TRAIL-resistance. (a) HCT116 wt and Bax /Bak cells were
pre-incubated with indicated concentrations of Mit A and downregulation of XIAP was observed upon immunoblotting (upper panel). Cells were then treated with TRAIL and
cultured for additional 24 h. Measurement of apoptotic cells by flow cytometry revealed that Mit A sensitized Bax/Bak-deficient cells for TRAIL-induced apoptosis. Data
expressed as mean values±S.D. from three experiments (lower panel). (b) To inhibit XIAP function, both cell lines were treated with 10mM of the SMAC mimetic LBW-242 in
addition to TRAIL. In HCT116 wt cells, TRAIL-induced caspase-3 processing was increased by LBW-242 (upper left). Increased caspase-3 processing was paralleled by
enhanced induction of apoptosis (lower left). In HCT116 Bax /Bak cells, pro-caspase-3 was cleaved upon TRAIL-treatment. Proteolytic fragments, however, were
detectable only upon addition of LBW-242 (upper right). Caspase-3 activation resulted in induction of apoptosis, indicating that LBW-242 can overcome TRAIL-resistance of
Bax/Bak-deficient HCT116 cells (lower right). Statistical significances were determined using an unpaired Student’s t-test. Levels of statistical significance are indicated with
asterisks (*Po0.05; **Po0.01)
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significantly extends other studies that identified the level of
caspase-8 activation upon death receptor activation as critical
discriminator between type I/II apoptosis signaling.5 Accord-
ing to this model, type I cells display strong activation of
caspase-8 upon death receptor ligation to directly activate
caspase-3, thereby bypassing the mitochondria. In contrast,
type II cells would generate only low amounts of active
caspase-8 at the DISC and strong activation of caspase-3
occurs at a level secondary to mitochondrial events. However,
in HCT116 cells caspase-8 activation induced by TRAIL is
sufficient to cleave pro-caspase-3 regardless of loss of Bax/
Bak expression. Nevertheless, pro-caspase-3 is processed
to its active subunits only in cells with an intact mito-
chondrial apoptotic-signaling pathway. In the absence of
MMP, caspase-3 subunits were degraded by the XIAP/
proteasome pathway. Upon activation of the mitochondria
through Bax/Bak, SMAC, released into the cytosol, inhibits
XIAP and prevents degradation of caspase-3 subunits resulting
in strong caspase-3 activation (Figure 7). Consequently,
inhibition of XIAP enables caspase-8 to directly induce
sufficient amounts of active caspase-3 in Bax/Bak-deficient
HCT116 cells thereby making SMAC release dispensable.
Taken together,wedemonstrate that it is not the extent of active
caspase-8 but the activity of XIAP, which makes a distinction
between cell death induction via a type II or type I pathway.
Pharmacological targeting of this type I/II switch would
overcome the need for Bax/Bak proficiency. In this vein, we
show that processing of pro-caspase-3 to its active subunits
without activation of the mitochondria can be enforced by
inhibition of the proteasome. Proteasome inhibitors may
sensitize tumor cells for TRAIL by enhanced cell surface
expression of TRAIL-R1 (DR4) and TRAIL-R2 (DR5),
enhanced activation of the initiator caspase-8 and down-
regulation of cFLIP.29,30 Furthermore, bortezomib-induced
stabilization of the Bax protein as well as increased levels of
Nbk/Bik and Bim were implicated in sensitization for TRAIL
killing.31,32 Our data suggest that the stabilization of active
caspase-3 by blocking its proteasomal degradation, by either
inhibiting proteasomal activity or preventing XIAP-mediated
ubiquitylation, is the main mechanism responsible for sensi-
tization. Interestingly, the caspase-3 fragments, which accu-
mulate upon proteasome inhibition in addition to TRAIL-
treatment, seem to be unubiquitinated (Figure 2a). Caspases
have been shown to inhibit XIAP by cleavage33 and this
Figure 6 XIAP mediates resistance to TNFa and CD95/FasL-induced
apoptosis in Bax/Bak-deficient HCT116 cells. (a) HCT116 wt cells were transfected
with control or XIAP-siRNA and cultured for 24 h. After knockdown of XIAP, cells
were treated with TNFa or CD95L/FasL and cultured for additional 24 h.
Measurement of apoptotic DNA fragmentation revealed that HCT116 wt cells were
sensitized toward TNFa- or CD95L/FasL-induced apoptosis upon downregulation of
XIAP. (b) HCT116 Bax /Bak cells were treated as in (a). Measurement of
apoptotic cells revealed that HCT116 Bax /Bak cells transfected with control
siRNA were resistant towards TNFa- or CD95L/FasL-induced cell death. However,
XIAP downregulation enabled TNFa and CD95L/FasL (TRAIL) to induce apoptosis
despite Bax/Bak deficiency. Data expressed as mean values±S.D. from three
experiments are shown. Levels of statistical significance are indicated with asterisks
(*Po0.05; **Po0.01)
Figure 7 Model of XIAP as a switch between type I and type II signaling. See
text for details. Mit A, Mithramycin A; BZM, bortezomib
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feedback loop might be responsible for the accumulation of
unubiquitinated active caspase-3 upon inhibition of the
proteasome. However, inhibition of the proteasome or XIAP
result in sufficient generation of active caspase-3 andmediate
a switch from a type II to a type I mode of cell death. This
notion is supported by experiments where we inhibited XIAP
function by the use of the synthetic small molecule IAP
inhibitor LBW-242 that mimics the activity of SMAC. LBW-242
is a promising compound to overcome drug resistance.34,35
Here, we show that LBW-242 overcomes resistance of Bax/
Bak-deficient cancer cells and re-sensitizes these cells to
TRAIL. Loss of both Bax or Bak expression has been reported
for a number of tumors.36–39Whereas loss of Bax is a frequent
event in human cancer, for example, in colon cancers having a
microsatellite mutator phenotype, Bak expression persists in
most cancers and loss of both is a rare event. Notably, loss of
Bax, despite expression of Bak, is sufficient for tumor cells to
acquire TRAIL-resistance. In addition, the intrinsic apoptotic
pathway of tumor cells can be blocked by other mechanisms,
for example, upregulation of Bcl-xL (which efficiently inhibits
both, Bax and Bak) or endogenous Bak-inhibitors Mcl-1 or
VDAC2 in Bax-deficient carcinoma.14,15,40 The data pre-
sented in this study indicate that use of SMAC mimetics is a
suitable strategy to antagonize therapy resistance caused by
all these central defects in the intrinsic apoptosis machinery
and delineates the combined use of TRAIL together with
SMAC mimetics as a useful strategy. Altogether, these data
show that targeting of XIAP enables death receptor signaling
to kill type II cells via a type I pathway and define XIAP as a
crucial decision point between these two cell death pathways.
Materials and Methods
Cell culture. HCT116 wild-type cells and the isogenic knockout subline
HCT116-Bax / were kindly provided by Dr. Bert Vogelstein, Johns Hopkins
Cancer Center, Baltimore, MD, USA. The stable knockdown of Bak shRNA was
achieved in HCT116-Bax k.o. cells yielding Bax /Bak cells.17 Mock
transfectants showed an identical apoptosis sensitivity as compared with
HCT116 parental cells (HCT116 wt). Cells were grown in DMEM medium
supplemented with 10% fetal calf serum, 100 000 U/l penicillin and 0.1 g/l
streptomycin at 37 1C with 5% CO2 in a fully humidified atmosphere. Media and
culture reagents were from Invitrogen (Karlsruhe, Germany).
Antibodies and reagents. SMAC/Diablo mAb (#2954), C-8 (1C12) mAb
(#9746) and XIAP mAb (3B6) (#2045) were purchased from Cell Signaling
Technology, Inc. (Boston, MA, USA). Bcl-2 antibody (NCL-bcl-2) was purchased
from Novocastra Laboratories (Newcastle, UK). The anti-Bak Ab (clone TC102) was
from Calbiochem (Darmstadt, Germany). Anti-Bax Ab (clone YTH-2D2) was
purchased from Trevigen (Gaithersburg, MD, USA) and anti-Mcl-1H-260 was from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-Bcl-x Ab was from BD
Biosciences Pharmingen (San Diego, CA, USA). Anti-caspase-8 (clone 12F5) was
from Alexis (Gru¨nberg, Germany). The anti-C-3 Ab and anti-Bid Ab were from R&D
Systems GmbH (Wiesbaden-Nordenstadt, Germany), anti-actin Ab was from Sigma-
Aldrich (Taufkirchen, Germany). Secondary anti-rabbit, anti-goat and anti-mouse
horseradish peroxidase-conjugated antibodies were from Promega (Mannheim,
Germany) or Southern Biotechnology Associates (Birmingham, AL, USA). RNase A
was from Roth (Karlsruhe, Germany). The recombinant human TRAIL was from
R&D Systems GmbH (Wiesbaden-Nordenstadt, Germany). TNFa and Super-
FasLigand were from Alexis (Gru¨nberg, Germany). MG132 was purchased from
Sigma-Aldrich, Mit A was from Genaxxon BioScience GmbH (Ulm, Germany). The
LBW-242 SMAC mimetic was kindly provided by Novartis (Basel, Switzerland).
RNA interference. On-target plus XIAP, Mcl-1, caspase-8, Bid and control
siRNA were purchased from Dharmacon (Lafayette, LA, USA). Transfection of the
cells was carried out by use of DharmaFECT Transfection Reagent according to
the manufacturer’s instructions. Downregulation of the respective proteins was
confirmed by immunoblotting 24 h after transfection.
Immunoblotting. After trypsination, cells were washed twice with ice-cold
PBS and lysed in 10 mM Tris-HCl pH 7.5, 137 mM NaCl, 1% Triton X-100, 2 mM
EDTA, 1mM pepstatin, 1 mM leupeptin and 0.1 mM phenylmethyl sulfonylfluoride
(PMSF). Protein concentration was determined using the bicinchoninic acid assay.
Equal amounts of protein were separated by SDS-PAGE, electroblotted and
visualized as described.41 For analysis of cytochrome c and SMAC release,
cytosolic extracts were prepared according to a method described previously.41
Briefly, after induction of apoptosis, cells were harvested in PBS, equilibrated in
hypotonic buffer (20 mM HEPES pH 7.4, 10 mM KCl, 2 mM MgCl2, 1 mM EDTA)
supplemented with 0.1 mM PMSF and 0.75 mg/ml digitonin (Sigma-Aldrich) and
incubated on ice for 3 min. Debris was pelleted by centrifugation at 10 000 g at
4 1C for 5 min and the supernatant was subjected to western blot analysis.
Measurement of mitochondrial permeability transition. Cells were
harvested and collected by centrifugation at 300 g at 4 1C for 5 min.
Mitochondrial permeability transition was determined by staining the cells with
JC-1 (5,50,6,60-tetrachloro-1,10,3,30-tetraethyl-benzimidazolylcarbocyanin iodide;
Molecular Probes, Leiden, The Netherlands), a cationic dye that exhibits
membrane potential-dependent accumulation in mitochondria, as described.41
Mitochondrial permeability transition was then quantified by flow cytometric
determination of cells with decreased red fluorescence, that is, with mitochondria
displaying a reduced membrane potential (DCm).
Measurement of apoptotic cell death by flow cytometry. DNA
fragmentation was measured as described.15 Briefly, cells were collected by
centrifugation at 300 g for 5 min, washed with PBS at 4 1C, and fixed in PBS/2%
(vol/vol) formaldehyde on ice for 30 min. After fixation, cells were incubated with
ethanol/PBS (2 : 1, vol/vol) for 15 min, pelleted, and resuspended in PBS
containing 40mg/ml RNase A. After incubation for 30 min at 37 1C, cells were
pelleted and finally resuspended in PBS containing 50 mg/ml PI. DNA
fragmentation was quantified by flow cytometric determination of hypodiploid
DNA. Data were collected and analyzed using a FACScan (Becton Dickinson,
Heidelberg, Germany) equipped with the CELLQuest software. Data are given in
% hypoploidy (subG1), which reflects the number of apoptotic cells. Alternatively,
cell death was determined by staining cells with Annexin V-fluorescein
isothiocyanate (FITC) and counterstaining with PI.15 Briefly, cells were washed
twice with cold PBS and resuspended in 10 mM N-[2-hydroxyethyl]piperazin-N0-
3[propansulfonicacid]/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2 at 1 106
cells/ml. Next, 5ml of Annexin V-FITC (BD PharMingen, Heidelberg, Germany)
and 10ml PI (20 g/ml, Sigma-Aldrich) were added. Analyses were performed using
a FACScan (Becton Dickinson) and CELLQuest analysis software. Results are
given in % of cells.
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